Chapter III. Diabetic Retinopathy

New Therapeutic Approaches in Diabetic Retinopathy

Kamyar Vaziri, Stephen G. Schwartz, Nidhi Relhan, Krishna S. Kishor, Harry W. Flynn Jr

Manuscript submitted April 24, 2015; accepted April 30, 2015.

Keywords: diabetic retinopathy, macular edema, proliferative diabetic retinopathy, vascular endothelial growth factor

Abstract

Diabetic retinopathy is a common microvascular complication of diabetes mellitus. It affects a substantial proportion of US adults over age 40. The condition is a leading cause of visual loss. Much attention has been given to expanding the role of current treatments along with investigating various novel therapies and drug delivery methods. In the treatment of diabetic macular edema (DME), intravitreal pharmacotherapies, especially anti-vascular endothelial growth factor (anti-VEGF) agents, have gained popularity. Currently, anti-VEGF agents are often used as first-line agents in center-involved DME, with recent data suggesting that among these agents, aflibercept leads to better visual outcomes in patients with worse baseline visual acuities. While photocoagulation remains the standard treatment for proliferative diabetic retinopathy (PDR), recent FDA approvals of ranibizumab and aflibercept in the management of diabetic retinopathy associated with DME may suggest a potential for pharmacologic treatments of PDR as well. Novel therapies, including small interfering RNAs, chemokines, kallikrein-kinin inhibitors, and various anti-angiogenic agents, are currently being evaluated for the management of diabetic retinopathy and DME. In addition to these strategies, novel drug delivery methods such as sustained-release implants and refillable reservoir implants are either under active evaluation or have recently gained FDA approval. This review provides an update on the novel developments in the treatment of diabetic retinopathy.

Fulltext: HTML , PDF (359KB)

This article has been cited by other articles:

	Efficacy of intravitreal bevacizumab combined with pan retinal photocoagulation versus panretinal photocoagulation alone in treatment of proliferative diabetic retinopathy Sameen M, Khan MS, Mukhtar A, Yaqub MA, Ishaq M Pak J Med Sci 2017. 33(1):142-145
	Inhibition of Hypoxia-Induced Retinal Angiogenesis by Specnuezhenide, an Effective Constituent of Ligustrum lucidum Ait., through Suppression of the HIF-1alpha/VEGF Signaling Pathway Wu J, Ke X, Fu W, Gao X, Zhang H, Wang W, Ma N, Zhao M, Hao X, Zhang Z Molecules 2016. 21(12):E1756
	Aloe-emodin suppresses hypoxia-induced retinal angiogenesis via inhibition of HIF-1alpha/VEGF pathway Wu J, Ke X, Wang W, Zhang H, Ma N, Fu W, Zhao M, Gao X, Hao X, Zhang Z Int J Biol Sci 2016. 12(11):1363-1371
	Histopathological and ophthalmoscopic evaluation of apocynin on experimental proliferative vitreoretinopathy in rabbit eyes Ozer MA, Polat N, Ozen S, Ogurel T, Parlakpinar H, Vardi N Int Ophthalmol 2016. In press
	Formononetin, an active compound of Astragalus membranaceus (Fisch) Bunge, inhibits hypoxia-induced retinal neovascularization via the HIF-1alpha/VEGF signaling pathway Wu J, Ke X, Ma N, Wang W, Fu W, Zhang H, Zhao M, Gao X, Hao X, Zhang Z Drug Des Devel Ther 2016. 10:3071-3081